FDA approval extended rituximab
The FDA has extended the approval of rituximab to first-line maintenance therapy in patients with follicular lymphoma.
The Food and Drug Administration (FDA) on 28 January 2011 Rituximab for first-line maintenance treatment of patients with advanced follicular lymphoma extends that previously responded to induction therapy with rituximab and chemotherapy. In the EU approval for this was in October 2010 had been granted (see med
0 comments:
Post a Comment